#China #Suzhou #Innovent Biologics #SYCUME #TYVYT

Innovent Biologics Expands Access to New Treatments

Innovent Biologics, a leading biopharmaceutical company based in China, has made a significant advancement in patient care by announcing the inclusion of seven of its innovative drugs in the updated 2025 National Reimbursement Drug List (NRDL). This decision will not only broaden accessibility to essential therapies but also enhance their affordability for patients across China.

Overview of the New Drug Approvals

Among the notable inclusions is a new indication for TYVYT® (sintilimab injection), which has been developed in collaboration with Eli Lilly and Company. This monoclonal antibody has gained approval for treatment across various cancers, including lung, liver, and gastric cancers, making it a powerful tool in oncology. Now, TYVYT has a newly approved indication for advanced endometrial cancer, a significant step in addressing gaps in treatment for patients who have failed previous therapies.

SYCUME® (teprotumumab N01 injection) is another groundbreaking addition. It is the first approved antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) in China and addresses moderate-to-severe thyroid eye disease (TED). This therapy represents a substantial breakthrough in non-invasive treatment options, improving the quality of life for patients who suffer from TED.

Other Noteworthy Medications

The updated NRDL also includes:

• - Limertinib, a third-generation EGFR TKI, providing vital options for patients with specific mutations in non-small cell lung cancer (NSCLC).
• - Dupert® (fulzerasib), a novel KRAS G12C inhibitor, offers new hope for NSCLC patients with this challenging mutation.
• - DOVBLERON® (taletrectinib) and Retsevmo® (selpercatinib) focus on locally advanced or metastatic forms of lung and thyroid cancers, addressing additional critical needs in oncology care.
• - Finally, Jaypirca® (pirtobrutinib) rounds out the list, serving patients with relapsed or refractory mantle cell lymphoma who have already undergone several treatments.

Dr. Michael Yu, the founder and CEO of Innovent, expressed his satisfaction regarding this inclusion, emphasizing the company's commitment to combating major public health challenges prevalent in China, particularly in oncology. He stated, “The inclusion of our new therapies in the NRDL will help more individuals and families access high-quality medications at affordable prices.”

Innovent's proactive approach in the biopharmaceutical industry is noteworthy. The company, founded in 2011, has continuously prioritized affordability and accessibility of its high-quality medicines, which extend beyond oncology to include treatments for cardiovascular, metabolic, autoimmune diseases, and eye diseases. With a total of 17 products launched and additional candidates in the pipeline, Innovent is positioned as a key player in addressing unmet medical needs.

Looking Ahead

Effective from January 1, 2026, these inclusions are expected to bridge significant gaps in treatment availability. Patients suffering from serious health conditions will benefit from the expanded access to innovative therapeutic options, fostering a more equitable healthcare landscape in China.

By aligning their advancements with patient-centric values, Innovent Biologics not only reaffirms its mission to empower patients but also sets a standard in the biopharmaceutical sector for the delivery of innovative and accessible treatments.

For more information about Innovent Biologics and their revolutionary therapies, please visit their official website.